Literature DB >> 28450561

Prognostic Value of Myocardial Perfusion Imaging with a Cadmium-Zinc-Telluride SPECT Camera in Patients Suspected of Having Coronary Artery Disease.

Elsemiek M Engbers1,2, Jorik R Timmer3, Mohamed Mouden3,2, Siert Knollema2, Pieter L Jager2, Jan Paul Ottervanger3.   

Abstract

The prognostic value of myocardial perfusion imaging (MPI) with the cadmium-zinc-telluride (CZT) SPECT camera is not well established. Therefore, the aim of the current study was to evaluate the prognostic value of MPI performed with a CZT SPECT camera in a large cohort of patients suspected of having coronary artery disease.
Methods: Consecutive symptomatic stable patients (n = 4,057) without a history of coronary artery disease underwent CZT SPECT MPI. During a median follow-up of 2.4 y (25th-75th percentile, 1.7-3.4), patients were monitored for primary (nonfatal myocardial infarction and cardiac mortality) and secondary outcomes (late revascularization [>90 d after scanning] and primary outcome).
Results: Patients with normal perfusion demonstrated low annual event rates (primary outcome, 0.2%; secondary outcome, 0.6%). Annual event rates increased with the extent of abnormality of myocardial perfusion. In patients with small ischemic perfusion defects, annual event rates were 0.7% and 2.8% for the primary and secondary outcome, respectively. In patients with moderate or large ischemic perfusion defects, these event rates were 1.2% and 4.3%, respectively. After multivariate analysis, the risk for events was significantly associated with the extent of ischemia (hazard ratio for small ischemic defects: 2.2, 95% confidence interval [CI], 0.9-5.9 and 4.6, 95% CI, 2.8-7.6, for primary and secondary outcomes, respectively; hazard ratio for moderate or large ischemic defects: 4.0, 95% CI, 1.5-10.5 and 12.1, 95% CI, 7.2-20.2, for primary and secondary outcomes, respectively).
Conclusion: Our findings show that MPI acquired with a CZT SPECT camera provides excellent prognostic information, with low event rates in patients with normal myocardial perfusion. In patients with abnormal SPECT MPI, the extent of abnormality is independently associated with an increased risk of events.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  SPECT; cadmium zinc telluride; prognosis; suspected coronary artery disease

Mesh:

Substances:

Year:  2017        PMID: 28450561     DOI: 10.2967/jnumed.116.188516

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

Review 1.  Emerging Tracers for Nuclear Cardiac PET Imaging.

Authors:  Dong-Yeon Kim; Sang-Geon Cho; Hee-Seung Bom
Journal:  Nucl Med Mol Imaging       Date:  2018-05-08

2.  5-Year Prognostic Value of Quantitative Versus Visual MPI in Subtle Perfusion Defects: Results From REFINE SPECT.

Authors:  Yuka Otaki; Julian Betancur; Tali Sharir; Lien-Hsin Hu; Heidi Gransar; Joanna X Liang; Peyman N Azadani; Andrew J Einstein; Mathews B Fish; Terrence D Ruddy; Philipp A Kaufmann; Albert J Sinusas; Edward J Miller; Timothy M Bateman; Sharmila Dorbala; Marcelo Di Carli; Balaji K Tamarappoo; Guido Germano; Damini Dey; Daniel S Berman; Piotr J Slomka
Journal:  JACC Cardiovasc Imaging       Date:  2019-06-12

Review 3.  Debates over NICE Guideline Update: What Are the Roles of Nuclear Cardiology in the Initial Evaluation of Stable Chest Pain?

Authors:  Sang-Geon Cho; Jahae Kim; Ho-Chun Song
Journal:  Nucl Med Mol Imaging       Date:  2019-08-28

4.  Polar map-free 3D deep learning algorithm to predict obstructive coronary artery disease with myocardial perfusion CZT-SPECT.

Authors:  Chi-Lun Ko; Shau-Syuan Lin; Cheng-Wen Huang; Yu-Hui Chang; Kuan-Yin Ko; Mei-Fang Cheng; Shan-Ying Wang; Chung-Ming Chen; Yen-Wen Wu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-14       Impact factor: 10.057

5.  Myocardial Flow Reserve Measurement During CZT-SPECT Perfusion Imaging for Coronary Artery Disease Screening: Correlation With Clinical Findings and Invasive Coronary Angiography-The CFR-OR Study.

Authors:  Matthieu Bailly; Frédérique Thibault; Maxime Courtehoux; Gilles Metrard; Denis Angoulvant; Maria Joao Ribeiro
Journal:  Front Med (Lausanne)       Date:  2021-06-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.